Figures & data
Fig. 1. Molecular structure of the AHLs used in this study (A) and IEC-6 cell proliferation in response to supplementation with AHL (B).
Note: Cells were exposed to various concentrations (0, 10−9, 10−8, 10−7, 10−6, 10−5, and 10−4 M) of AHLs (C8-HSL, C10-HSL, C12-HSL, 3-oxo-C8-HSL, 3-oxo-C10-HSL, 3-oxo-C12-HSL, and 3-oxo-C14-HSL). The highest concentration appears to the right in each panel. Values are arbitrary units and are expressed as averages with SEM (n = 4).
*Significant difference from control (p < 0.05).
Fig. 2. Proportion of the sub-G1 phase in IEC-6 cells subjected to AHL treatment.
Note: Cells were exposed to AHLs (control, C10-HSL, C12-HSL, 3-oxo-C10-HSL, 3-oxo-C12-HSL, or 3-oxo-C14-HSL) at 100 μM for 18 h. Representative histograms of propidium iodide incorporation in the cells in response to each of the AHL (A). Percentages of cells in the sub-G1 phase in response to each of the AHL (B). Values are expressed as averages with SEM (n = 4). Values with different letters are significantly different (p < 0.05).
Fig. 3. Effects of AHLs on mucosal permeability of the isolated rat colon.
Note: Colonic mucosa was isolated from rats and mounted in an Ussing chamber. Lucifer yellow (100 μM) and AHLs were added to the mucosal chamber and this was incubated for 60 min. The LY concentration in the serosal chamber was measured as permeability marker. Values are arbitrary units and are expressed as averages with SEM (n = 4).
*Significant difference from control (p < 0.05).
